The Danish Directorate General of Health announced on April 14 that they will permanently cancel the use of the AstraZeneca vaccine against COVID. Yes, for a month, they stopped using this drug because it is related to a rare blood clot.
Why did Denmark permanently stop the use of AstraZeneca vaccine?
According to the information country, The Danish health authorities stated that they agree with the European Medicines Agency (EMA) that the AstraZeneca vaccine is “Safe and effective”. However, Tanja Erichsen, the head of the local drug administration, recalled that the decision to suspend the use of the drug depends on each country.
Simultaneously, Sren Brostrm, director of the General Administration of Health, said that they know there is a possible biological explanation that the AstraZeneca vaccine may cause rare blood clot cases. But he pointed out at the press conference that there is a temporary link between symptoms and vaccination.
They pointed out that the risk of vaccinated people is one in 40,000
The Danish authorities, together with Norway, conducted several studies in another country where AstraZeneca’s vaccination was suspended, estimating: For people who have been vaccinated, the risk of these symptoms is one in 40,000 and cannot be reduced to certain age groups or genders.
In this regard, Brosstrm added that they have sufficient evidence for the Danish authorities to decide to suspend the use. Although he did not refuse, they can use the vaccine again if necessary in the future.
They will use a second dose of other vaccines
With this decision, approximately 149,000 people in Denmark will now receive the first dose of AstraZeneca’s second dose.. In addition, the vaccination schedule will be delayed by several weeks, and the authorities consider the entire population to end in early August.
It should be noted that this day The Pan American Health Organization (PAHO), a regional body of the World Health Organization (WHO), recommends the continued use of the AstraZeneca vaccine, Because it may be related to a rare blood clot, it is under review.
*Information from country